|
|
Article: Ranbaxy Is Granted Approval to Market Amoxicillin and Clavulanate Potassium Tablets USP (Chewable).
- Article from:
- PR Newswire
- Article date:
- December 4, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PRINCETON, N.J., Dec. 4 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the Office of Generic Drugs of the U.S. Food and Drug Administration to manufacture and market Amoxicillin and Clavulanate Potassium Tablets USP (Chewable), 200 mg/28.5 mg (base) and 400 mg/57 mg (base). The Division of Bioequivalence has determined Ranbaxy's Amoxicillin and Clavulanate Potassium Tablets USP (Chewable), 200 mg/28.5 mg (base) and 400 mg/57 mg (base), to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Augmentin(R) Chewable ...